The abstract is read at the publisher; the summary is JClub's.
Nemolizumab is assessed for effectiveness and safety in patients with severe pruritus associated with cutaneous T-cell lymphoma.
- Why it matters: Severe pruritus in cutaneous T-cell lymphoma creates a major unmet need for therapies that are both effective and safe, especially around diagnosis timing.
- What they did: The study evaluates nemolizumab outcomes and adverse effects in routine clinical use when given before or after cutaneous T-cell lymphoma diagnosis.
- The result: Findings are intended to clarify how nemolizumab performs in real-world treatment of severe pruritus in this patient population, informing clinical use around diagnosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.